Migco Pharmaceuticals

MGX-008, Migco's lead compound, is derived from the bark of Pinus radiata and represents a new approach to migraine prevention. Opportunities are also emerging for the treatment of other neurological conditions including ADHD and Alzheimers.

Migco has clinical safety data for MGX-008, successful human concept trials, and a highly skilled and experienced scientific management and governance team to manage the process through to market.

The company's target market is severe migraine sufferers - more than 28 million in the US alone. To reach them, Migco intends MGX-008 to be marketed as a prescription medicine. 

With a network of collaborations with leading neurologists, scientists and geneticists, Migco has established commercial alliances with manufacturers, contract research organizations and advisory consultants across the US, Britain, India, Australia and New Zealand.

Website: http://www.migco.com/

The company profiled is one of the investment opportunities currently available in New Zealand. Please note that these opportunities are not endorsed or recommended by New Zealand Trade and Enterprise (NZTE) and may be updated from time to time. Investors are advised to contact our New Zealand-based Investment Specialist to discuss further and to conduct their own due diligence and independent advice on the relevant investment, before committing to any investment.